Health

AstraZeneca's Lung Cancer Drug Update

Updated 2026-08-17 13:55 UTC 1 source Negative

Europe has pulled AstraZeneca’s lung cancer drug Tavneos due to trial integrity concerns. The company is facing additional pricing issues with its hypertension drug, Akeso.

Coverage timeline — 1 article

STAT News

STAT+: Akeso and Summit’s lung cancer drug shows worsening tumor-progression benefit

Europe pulls Tavneos over trial integrity concerns, pricing concerns over AstraZeneca's hypertension drug, and more biotech news from The Readout

2026-08-17 13:38 UTC